hippurin: from gorgonian Isis hippuris; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 128330 |
| CHEMBL ID | 508041 |
| CHEBI ID | 185496 |
| MeSH ID | M0119732 |
| Synonym |
|---|
| hippurin |
| CHEMBL508041 |
| epihippurin 1 |
| CHEBI:185496 |
| [(1s,2s,3's,4s,6s,7r,8r,9s,11s,12s,13s,15r,16s,18s)-7,11,16-trihydroxy-2',2',3',7,9,13-hexamethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,5'-oxolane]-15-yl] acetate |
| 22-epi-hippurin-1 |
| 66536-82-1 |
| (22s)-1alpha-acetoxy-5alpha-furospirostan-3alpha,11beta,20r-triol |
| LMST01090004 |
| 24-methyl-22,25-epoxy-5alpha-furostan-2,3,11,20-tetrol 2-monoacetate |
| furostan-2,3,11,20-tetrol, 22,25-epoxy-24-methyl-, 2-acetate, (2alpha,3alpha,5alpha,11beta,22alpha,24s)- |
| bdbm50482556 |
| DTXSID00985146 |
| 3,11,20-trihydroxy-24-methyl-22,25-epoxyfurostan-2-yl acetate |
| Class | Description |
|---|---|
| steroid | Any of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from squalene which is a triterpene. |
| oxaspiro compound | A spiro compound in which at least one of the cyclic components is an oxygen heterocyle. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Eukaryotic initiation factor 4A-I | Mus musculus (house mouse) | IC50 (µMol) | 100.0000 | 0.4000 | 0.4000 | 0.4000 | AID503175 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytosol | Eukaryotic initiation factor 4A-I | Mus musculus (house mouse) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID402290 | Cytotoxicity against human MCF7 cells after 3 days by MTT assay | 2005 | Journal of natural products, Jun, Volume: 68, Issue:6 | Polyoxygenated steroids from the gorgonian Isis hippuris. |
| AID402289 | Cytotoxicity against human Hep3B cells after 3 days by MTT assay | 2005 | Journal of natural products, Jun, Volume: 68, Issue:6 | Polyoxygenated steroids from the gorgonian Isis hippuris. |
| AID402288 | Cytotoxicity against human HepG2 cells after 3 days by MTT assay | 2005 | Journal of natural products, Jun, Volume: 68, Issue:6 | Polyoxygenated steroids from the gorgonian Isis hippuris. |
| AID503175 | Inhibition of eIF4A-mediated cap-dependent protein synthesis in FF-HCV-Ren mRNA transfected Swiss mouse Krebs2 cell extract by [35S]methionine metabolic labeling study | 2006 | Nature chemical biology, Apr, Volume: 2, Issue:4 | Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. |
| AID402291 | Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay | 2005 | Journal of natural products, Jun, Volume: 68, Issue:6 | Polyoxygenated steroids from the gorgonian Isis hippuris. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (59.53) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||